INTRODUCTION
It is estimated that there are 65,697 new cases of ovarian cancer and 41,448 deaths in Europe each year (1) . Ovarian cancer is among the sixth leading cancers in Vojvodina and the fifth leading cause of cancer death among female population in Vojvodina according to Cancer Registry of Vojvodina in 2010 (2) . Only one fourth of women present with localized disease at diagnosis. The majority of ovarian cancer cases are diagnosed at an advanced stage of disease (FIGO stage III-IV) (3) . The prognosis for survival from ovarian cancer is largely dependent upon the extent of disease at diagnosis. Approximately 15% of patients are presented with disease confined to the ovaries and after surgery, their 5-year survival is more than 90%. A 5-year survival among patients with advanced disease (FIGO stage III-IV) is less than 30% (4) . The etiology of ovarian cancer is poorly understood. Early diagnostic of ovarian cancer is mandatory. Still, there is not enough sensitive diagnostic tool for early detection that can be recommended. There are numerous methods that have been tested in the preoperative identification of adnexal masses suspicious for malignancy. The results of some trials have reported the efficacy of screening of asymptomatic women with annual measurement of CA 125 and transvaginal ultrasound examination but they have failed to demonstrate a reduction in mortality (5) . Risk factors for developing ovarian cancer are numerous: ages (over 50), gene mutation (BRCA 1, BRCA 2, and Lynch II syndrome), geographic variations (higher incidence in North America, and North Europe), reproductive factors (nullipara, infertility), and hormonal factors (6) . The most common histopathological type of ovarian cancer is epithelial cancer and the most common histological subtype is serous carcinoma (7) . The clinical symptoms of early ovarian cancer are nonspecific such as abdominal pain, bloating, changes in bowel frequency, and urinary and/or pelvic symptoms (8) (9) (10) In both regions, the most frequent was serous subtype of epithelial ovarian cancer: 299/530 patients in Vojvodina (average: 49.83 pt /year) and 126/157 (average: 21 pt/year) in SGP (p≤0.05). Endometrioid and mucinous subtypes were more common among women in Vojvodina than in SGP but difference was not significant (p>0.05) (Figure 2 (Figure 4 ). As the distribution of ovarian cancer cases by FIGO stage classification was without statistical significance, we created linear trends using epidemiological data from Vojvodina. The linear trends of the reported cases in FIGO stage I and II for the period 2007-2012 showed ascending trends but it was also without statistical significance (p>0.05) (Figures 5 and 6 ). Epidemiological data for FIGO stages III and IV are summarized ( Figure 7 ) and linear trend showed only moderate descending (p>0.05). The average age of patient with diagnosed ovarian cancer was 55.94 years. The patients diagnosed with FIGO stage I and II were younger than patients with advanced disease (FIGO stage III-IV) in both regions. The difference in average age of patients based on FIGO classification was statistically significant (p < 0.0001) only for patients from Vojvodina ( Figure 8 ). Ovarian cancer was diagnosed in most patients that were older than 50 years,(p < 0.0001) (Figure 9 ).
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DISCUSSION
The ovarian cancer is estimated as the most lethal malignant gynecological oncologic disease. The majority of the newly diagnosed cases are in advanced disease (3). In our study, majority of patients (≥60 %) were diagnosed in advanced disease, FIGO stage III-IV, in both Vojvodina, Serbia and South Great Plain, Hungary. The results are comparable with UK epidemiological data where the most women are also diagnosed with advanced stage disease: 60% stage III, IV, and around 30% in the early stages I and II (13) . Similar results reported Malenkovic et al. (14) for period 2001-2008 in Vojvodina. In both regions, we found similar percent The results of histopathological analyses were also similar in our both regions. The most common epithelial ovarian cancer subtype in both regions was serous ovarian cancer. In 2009 in UK serous subtype accounted for one-third of all cases which is comparable with number of newly diagnosed serous ovarian cancer in Vojvodina (16) . The higher prevalence of the serous ovarian cancer was diagnosed in South Great Plain. One of the reasons for such significant differences between two regions may be the higher percentage of unknown histopathological type: 18.82% in Vojvodina population and only 6.86% in South Great Plain. Ovarian cancer is predominantly a disease of older women. Usually, it is diagnosed in women age around 60 years (3). The average age of patients in our study was 55.94 without significant difference between both regions. Our patients were older than 50 years in more than 80% that is in agreement with previous UK report (16) . In our study, advanced disease showed a moderate descending linear trend. Malenković et al. study (14) for the period 2001-2008 in Vojvodina, showed ascending linear trend, but also without statistical significance (14) . Diagnostic approaches in the preoperative identification of ovarian malignancy were also studied (17) (18) (19) (20) (21) (22) . It is suggested that 3D ultrasonography has higher sensitivity and specificity compared to 2D ultrasound (18, 19) . In addition, morphological scoring systems have satisfying sensitivity and specificity (20) (21) (22) . Explicit scoring systems such as risk of malignancy index (RMI), is based on the score obtained by ultrasound (U), menopausal status (M), and CA-125 data in the following manner: RMI=U×M×CA-125. A cutoff of 200 was used to differentiate between malignant and benign masses in the original study (13) .Two studies reported on diagnostic accuracy of RMI (23, 24) . The overall sensitivity and specificity were 79.2% and 91.7%, respectively. These data were obtained by bivariate random effects model from 13 studies with 15 data sets (23, 24) . In evaluation of the three imaging modalities (NMR, CT, PET), NMR appeared the best, but results were not statistically different from CT. PET did not have any better performance than CT or NMR. Tumor biomarker CA 125 was also considered for diagnosis of ovarian cancer. However, its frequent measurement was found to be less reliable than other available assessment methods. In summary, results of bivariate analysis of 51 studies (52 data sets) showed that overall sensitivity was 78.7% and specificity was 77.9% (17) .
CONCLUSION
The vast majority of newly diagnosed ovarian cancer in Vojvodina, Serbia and South Great Plain, Hungary were patients with advanced disease stages. Newly diagnosed ovarian cancer was mostly found in women over 50 years old. Trends of FIGO classified stages in evaluated period did not show statistically significance fluctuation. The most diagnosed histological type was epithelial ovarian cancer and serous subtype in both regions. The results were comparable and similar to epidemiological data from the literature. 
